Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Abbott Settlement With DOJ Highlights Feds’ Anti-Fraud Efforts

This article was originally published in The Gray Sheet

Executive Summary

Abbott will pay $5.47 million to resolve allegations that it paid physicians for teaching assignments, speaking engagements and conferences with the expectation that they would in return facilitate product purchases at their hospitals.

You may also be interested in...



Abbott Wins Off-Label Stent Marketing Suit

A former Guidant salesman alleged the company marketed biliary stents off-label for use in vascular procedures. However, the company said Medicare knew biliary stents were the standard of care for arterial uses. A Texas jury sided with Abbott.

Sebelius HHS Tenure Dominated By ACA Coverage, But Also Focused On Fraud, Transparency

HHS Secretary Kathleen Sebelius is resigning, and Office of Management and Budget Director Sylvia Mathews Burwell has been nominated to take over her cabinet post, President Obama announced April 11.

C.R. Bard Pays $48 Million To Settle Brachytherapy False Claims Act Allegations

The settlement addresses allegations by the Justice Department that the company provided kickbacks to Medicare customers and physicians from 1998 to 2006 to purchase brachytherapy seeds used to treat prostate cancer.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT032784

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel